Glycorex Transplantation AB (publ), a medical technology company, engages in the development, production, and sale of products for use in organ transplantation. It develops a molecular level nanosurgical technology that specifically selects and removes antibodies in the blood focusing areas within transplants, blood transfusion, and blood products, as well as autoimmune disease. The company's principal product is Glycosorb-ABO, which facilitates the transplantation of organs over the blood group barriers that is used for the blood group-incompatible kidney, liver, heart, lungs, pancreatic, and stem cells transplantation procedures. It also offers Glycosorb UBP, a blood donor plasma tool for the treatment of donor blood. It serves in Europe, Austria, France, Germany, the Netherlands, and Spain. Glycorex Transplantation AB (publ) was incorporated in 1995 and is headquartered in Lund, Sweden.